Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Therapeutics and Clinical Risk Management Volume 4, 2008 - Issue 1

Submit an article Journal homepage

Open access

368

Views

CrossRef citations to date

Altmetric

Review

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec^®, Gleevec™)

Martin Henkes1 2nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch HospitalAuerbachstr. 110, Stuttgart, Germany

Heiko van der Kuip2 Dr Margarete Fischer-Bosch Institute of Clinical PharmacologyAuerbachstr. 112, Stuttgart, and University of Tuebingen, GermanyCorrespondence[email protected]

Walter E Aulitzky1 2nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch HospitalAuerbachstr. 110, Stuttgart, Germany

Pages 163-187 | Published online: 28 Dec 2022

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Onur Kirkizlar & Ahmet Emre Eskazan. (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Review of Quality of Life in Cancer Care 1:5, pages 353-359.
Read now

Yusuf Baran & Guray Saydam. (2012) Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. Journal of Blood Medicine 3, pages 139-150.
Read now

Yusuf Baran, Coskun Oztekin & Esen Yonca Bassoy. (2010) Combination of Fludarabine and Imatinib Induces Apoptosis Synergistically Through Loss of Mitochondrial Membrane Potential and Increases in Caspase-3 Enzyme Activity in Human K562 Chronic Myleloid Leukemia Cells. Cancer Investigation 28:6, pages 623-628.
Read now

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references